SARS-CoV-2 Neutralizing Antibody ELISA kit
Icosagen SARS-CoV-2 Neutralizing Antibody ELISA kit provides a rapid and easy method for qualitative in-vitro determination of neutralizing antibodies in human serum or plasma.
APPLICATION
The kit includes reagents necessary to analyze SARS-CoV-2 specific antibodies in up to 46 samples using one kit.|
Catalogue No
| Antibodies against
| Ig class |
Substrate |
Format
|
|
K5-002-096
|
SARS-Coronavirus-2 (SARS-CoV-2) trimeric spike protein | All classes |
Antigen-coated microtiter plate wells
|
96-well plate
|
INTENDED USE
The kit applies for detecting the presence of neutralizing anti-trimeric spike antibodies that have the capacity to neutralize the binding of trimeric spike protein to ACE2 (angiotensin-converting enzyme 2) receptor.CROSS-REACTIVITY
The Icosagen Neutralizing antibody kit was evaluated for potential cross-reactivity from a total of 165 specimens representing different medical conditions. All 165 specimens showed no cross-reactivity.|
Condition |
Group |
Samples |
Positive |
Negative |
False positive |
|
Physiological factors |
Pregnancy |
46 |
0 |
46 |
0% |
|
Immunological factors |
HIV+ (human immunodeficiency virus) |
29 |
0 |
29 |
0% |
|
HCV+ (hepatitis C virus) |
10 |
0 |
10 |
0% |
|
|
HSV+ (herpes simplex virus) |
10 |
0 |
10 |
0% |
|
|
ANA+ (anti-nuclear antibodies) |
10 |
0 |
10 |
0% |
|
|
EBV+ (Ebstein-Barr virus) |
10 |
0 |
10 |
0% |
|
|
CMV+ (cytomegalovirus) |
10 |
0 |
10 |
0% |
|
|
Lyme disease (anti-borrelia antibodies) |
10 |
0 |
10 |
0% |
|
|
Pneumonia (chlamydia infection) |
10 |
0 |
10 |
0% |
|
|
Pneumonia (mycoplasma infection) |
10 |
0 |
10 |
0% |
|
|
Rheumatoid arthritis (anti-rheumatoid factor antibodies) |
10 |
0 |
10 |
0% |
CLINICAL PERFORMANCE
Total of 735 specimens were tested using the Icosagen SARS-CoV-2 Neutralizing Antibody ELISA kit.The sensitivity, specificity, accuracy, positive percent agreement (PPA) and negative percent agreement (NPA) values for the Icosagen Covid-19 ELISA kit are shown in the following table:
|
Sensitivity |
Specificity |
Accuracy |
PPA |
NPA |
False negative* |
False positive** |
|
84.6% |
96.6% |
90.3% |
92.0% |
89.3% |
48 |
23 |
as well as not all the antibodies which neutralize the binding of spike protein to ACE2 have epitopes in the RBD region.